SK4794A3 - 4-pyromidione derivatives salts and pharmaceutical compositions containing this derivatives - Google Patents

4-pyromidione derivatives salts and pharmaceutical compositions containing this derivatives Download PDF

Info

Publication number: SK4794A3
Authority: SK; Slovakia
Prior art keywords: salts; tetrazol; phenylethyl; butyl; derivatives
Prior art date: 1993-01-15

Application number

SK47-94A

Other languages

English (en)

Slovak (sk)

Inventor

Christian Hoornaert

Alexander E Wick

Original Assignee

Synthelabo

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1993-01-15

Filing date

1994-01-14

Publication date

1995-01-12

1994-01-14 Application filed by Synthelabo filed Critical Synthelabo

1995-01-12 Publication of SK4794A3 publication Critical patent/SK4794A3/sk

Links

150000003839 salts Chemical class 0.000 title claims abstract description 18
239000008194 pharmaceutical composition Substances 0.000 title claims 2
-1 1H-tetrazol-5-yl group Chemical group 0.000 claims abstract description 12
150000001413 amino acids Chemical class 0.000 claims abstract description 4
239000003814 drug Substances 0.000 claims abstract 2
125000001072 heteroaryl group Chemical group 0.000 claims abstract 2
125000000896 monocarboxylic acid group Chemical group 0.000 claims abstract 2
150000001875 compounds Chemical class 0.000 claims description 15
125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 claims description 13
KDXKERNSBIXSRK-UHFFFAOYSA-N lysine Chemical class NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 10
DNCYBUMDUBHIJZ-UHFFFAOYSA-N 1h-pyrimidin-6-one Chemical compound O=C1C=CN=CN1 DNCYBUMDUBHIJZ-UHFFFAOYSA-N 0.000 claims description 8
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 8
125000004432 carbon atom Chemical group C* 0.000 claims 3
125000000217 alkyl group Chemical group 0.000 claims 1
125000003710 aryl alkyl group Chemical group 0.000 claims 1
125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
239000000546 pharmaceutical excipient Substances 0.000 claims 1
125000000286 phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 claims 1
125000006273 (C1-C3) alkyl group Chemical group 0.000 abstract 2
125000006701 (C1-C7) alkyl group Chemical group 0.000 abstract 1
125000003118 aryl group Chemical group 0.000 abstract 1
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 36
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 15
ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 10
239000002244 precipitate Substances 0.000 description 8
239000000203 mixture Substances 0.000 description 7
239000000243 solution Substances 0.000 description 7
239000000047 product Substances 0.000 description 6
238000003756 stirring Methods 0.000 description 6
241001465754 Metazoa Species 0.000 description 5
YWEUIGNSBFLMFL-UHFFFAOYSA-N diphosphonate Chemical compound O=P(=O)OP(=O)=O YWEUIGNSBFLMFL-UHFFFAOYSA-N 0.000 description 5
DLYUQMMRRRQYAE-UHFFFAOYSA-N phosphorus pentoxide Inorganic materials O1P(O2)(=O)OP3(=O)OP1(=O)OP2(=O)O3 DLYUQMMRRRQYAE-UHFFFAOYSA-N 0.000 description 5
CUKWUWBLQQDQAC-VEQWQPCFSA-N (3s)-3-amino-4-[[(2s)-1-[[(2s)-1-[[(2s)-1-[[(2s,3s)-1-[[(2s)-1-[(2s)-2-[[(1s)-1-carboxyethyl]carbamoyl]pyrrolidin-1-yl]-3-(1h-imidazol-5-yl)-1-oxopropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-methyl-1-ox Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C)C(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C1=CC=C(O)C=C1 CUKWUWBLQQDQAC-VEQWQPCFSA-N 0.000 description 4
102000005862 Angiotensin II Human genes 0.000 description 4
101800000733 Angiotensin-2 Proteins 0.000 description 4
229950006323 angiotensin ii Drugs 0.000 description 4
ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 4
ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical group C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 4
238000002844 melting Methods 0.000 description 4
230000008018 melting Effects 0.000 description 4
239000011541 reaction mixture Substances 0.000 description 4
239000000725 suspension Substances 0.000 description 4
241000700159 Rattus Species 0.000 description 3
238000010521 absorption reaction Methods 0.000 description 3
230000004872 arterial blood pressure Effects 0.000 description 3
239000006260 foam Substances 0.000 description 3
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
229920000742 Cotton Polymers 0.000 description 2
208000010412 Glaucoma Diseases 0.000 description 2
206010020772 Hypertension Diseases 0.000 description 2
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
239000002253 acid Substances 0.000 description 2
230000003042 antagnostic effect Effects 0.000 description 2
235000010290 biphenyl Nutrition 0.000 description 2
239000002775 capsule Substances 0.000 description 2
238000006243 chemical reaction Methods 0.000 description 2
230000000694 effects Effects 0.000 description 2
229940100692 oral suspension Drugs 0.000 description 2
239000000843 powder Substances 0.000 description 2
239000007787 solid Substances 0.000 description 2
NWLPRJINWFMRHH-UHFFFAOYSA-N 1-methylpyrimidin-4-one Chemical compound CN1C=CC(=O)N=C1 NWLPRJINWFMRHH-UHFFFAOYSA-N 0.000 description 1
229940127291 Calcium channel antagonist Drugs 0.000 description 1
JZUFKLXOESDKRF-UHFFFAOYSA-N Chlorothiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NCNS2(=O)=O JZUFKLXOESDKRF-UHFFFAOYSA-N 0.000 description 1
239000001828 Gelatine Substances 0.000 description 1
238000004566 IR spectroscopy Methods 0.000 description 1
ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 1
KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
MLMOCRARWOHJFN-UHFFFAOYSA-N N(CCO)CCO.N1=CN=CC=C1 Chemical compound N(CCO)CCO.N1=CN=CC=C1 MLMOCRARWOHJFN-UHFFFAOYSA-N 0.000 description 1
LUZMWNFHQNWMJU-UHFFFAOYSA-N NC(CCCCN)C(=O)O.N1=CN=CC=C1 Chemical compound NC(CCCCN)C(=O)O.N1=CN=CC=C1 LUZMWNFHQNWMJU-UHFFFAOYSA-N 0.000 description 1
238000005481 NMR spectroscopy Methods 0.000 description 1
239000002160 alpha blocker Substances 0.000 description 1
229940124308 alpha-adrenoreceptor antagonist Drugs 0.000 description 1
LTZNZBOEBQPMEQ-UHFFFAOYSA-N azide;hydrochloride Chemical compound Cl.[N-]=[N+]=[N-] LTZNZBOEBQPMEQ-UHFFFAOYSA-N 0.000 description 1
239000002876 beta blocker Substances 0.000 description 1
229940097320 beta blocking agent Drugs 0.000 description 1
230000017531 blood circulation Effects 0.000 description 1
230000000747 cardiac effect Effects 0.000 description 1
230000005792 cardiovascular activity Effects 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
125000001664 diethylamino group Chemical class [H]C([H])([H])C([H])([H])N(*)C([H])([H])C([H])([H])[H] 0.000 description 1
239000002934 diuretic Substances 0.000 description 1
229940030606 diuretics Drugs 0.000 description 1
238000001914 filtration Methods 0.000 description 1
238000009472 formulation Methods 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
239000007903 gelatin capsule Substances 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
238000010438 heat treatment Methods 0.000 description 1
229960002003 hydrochlorothiazide Drugs 0.000 description 1
230000001631 hypertensive effect Effects 0.000 description 1
239000003112 inhibitor Substances 0.000 description 1
230000010354 integration Effects 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
210000004072 lung Anatomy 0.000 description 1
229960003646 lysine Drugs 0.000 description 1
238000005259 measurement Methods 0.000 description 1
238000000034 method Methods 0.000 description 1
238000004452 microanalysis Methods 0.000 description 1
230000007170 pathology Effects 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
229920000136 polysorbate Polymers 0.000 description 1
230000002269 spontaneous effect Effects 0.000 description 1
239000008174 sterile solution Substances 0.000 description 1
239000000126 substance Substances 0.000 description 1
230000009897 systematic effect Effects 0.000 description 1
230000004873 systolic arterial blood pressure Effects 0.000 description 1
230000035488 systolic blood pressure Effects 0.000 description 1
239000003826 tablet Substances 0.000 description 1
230000000699 topical effect Effects 0.000 description 1
238000005303 weighing Methods 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/34—One oxygen atom
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives

Landscapes

Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Engineering & Computer Science (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Ophthalmology & Optometry (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)

SK47-94A 1993-01-15 1994-01-14 4-pyromidione derivatives salts and pharmaceutical compositions containing this derivatives SK4794A3 (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
FR9300340A FR2700543B1 (fr)	1993-01-15	1993-01-15	Sels de dérivés de 4-pyrimidinone, leur préparation et leur application en thérapeutique.

Publications (1)

Publication Number	Publication Date
SK4794A3 true SK4794A3 (en)	1995-01-12

Family

ID=9443056

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SK47-94A SK4794A3 (en)	1993-01-15	1994-01-14	4-pyromidione derivatives salts and pharmaceutical compositions containing this derivatives

Country Status (16)

Country	Link
EP (1)	EP0607077A1 (xx)
JP (1)	JPH06271548A (xx)
KR (1)	KR940018365A (xx)
CN (1)	CN1096783A (xx)
AU (1)	AU5317694A (xx)
CA (1)	CA2113491A1 (xx)
CZ (1)	CZ9494A3 (xx)
FI (1)	FI940185A (xx)
FR (1)	FR2700543B1 (xx)
HU (1)	HUT70193A (xx)
IL (1)	IL108342A0 (xx)
NO (1)	NO940131L (xx)
NZ (1)	NZ250678A (xx)
PL (1)	PL301900A1 (xx)
SK (1)	SK4794A3 (xx)
ZA (1)	ZA94290B (xx)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
KR19990081093A (ko)	1998-04-25	1999-11-15	조생현	피리미디논 화합물, 이를 함유하는 약제학적 조성물 및 이의제조방법
GB0914287D0 (en) *	2009-08-14	2009-09-30	Pci Biotech As	Compositions

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2672892B1 (fr) *	1991-02-20	1994-01-14	Synthelabo	Derives de 4-pyrimidinones, leur preparation et leur application en therapeutique.

1993
- 1993-01-15 FR FR9300340A patent/FR2700543B1/fr not_active Expired - Fee Related
1994
- 1994-01-11 EP EP94400058A patent/EP0607077A1/fr not_active Withdrawn
- 1994-01-14 FI FI940185A patent/FI940185A/fi not_active Application Discontinuation
- 1994-01-14 AU AU53176/94A patent/AU5317694A/en not_active Abandoned
- 1994-01-14 SK SK47-94A patent/SK4794A3/sk unknown
- 1994-01-14 KR KR1019940000599A patent/KR940018365A/ko not_active Application Discontinuation
- 1994-01-14 JP JP6002469A patent/JPH06271548A/ja active Pending
- 1994-01-14 IL IL10834294A patent/IL108342A0/xx unknown
- 1994-01-14 NO NO940131A patent/NO940131L/no unknown
- 1994-01-14 CZ CZ9494A patent/CZ9494A3/cs unknown
- 1994-01-14 PL PL94301900A patent/PL301900A1/xx unknown
- 1994-01-14 CN CN94100610A patent/CN1096783A/zh active Pending
- 1994-01-14 NZ NZ250678A patent/NZ250678A/en unknown
- 1994-01-14 ZA ZA94290A patent/ZA94290B/xx unknown
- 1994-01-14 CA CA002113491A patent/CA2113491A1/en not_active Abandoned
- 1994-01-14 HU HU9400108A patent/HUT70193A/hu unknown

Also Published As

Publication number	Publication date
HUT70193A (en)	1995-09-28
PL301900A1 (en)	1994-07-25
NO940131D0 (no)	1994-01-14
AU5317694A (en)	1994-07-21
CZ9494A3 (en)	1994-08-17
FI940185A (fi)	1994-07-16
FI940185A0 (fi)	1994-01-14
NO940131L (no)	1994-07-18
JPH06271548A (ja)	1994-09-27
FR2700543B1 (fr)	1995-03-17
HU9400108D0 (en)	1994-05-30
EP0607077A1 (fr)	1994-07-20
CN1096783A (zh)	1994-12-28
NZ250678A (en)	1994-10-26
KR940018365A (ko)	1994-08-16
ZA94290B (en)	1994-08-17
FR2700543A1 (fr)	1994-07-22
CA2113491A1 (en)	1994-07-16
IL108342A0 (en)	1994-04-12

Publication	Publication Date	Title
AU782307B2 (en)	2005-07-21	Dihydro-1,3,5-triazine amine derivatives and their therapeutic uses
DE69633245T2 (de)	2005-09-08	Spiroverbindungen als Inhibitoren der Fibrinogen-abhängigen Blutplättchenaggregation
ES2248124T3 (es)	2006-03-16	4-aminopteridinas n-sustituidas, procedimiento para su obtencion y utilizacion de las mismas como medicamentos.
PT95929A (pt)	1991-09-13	Processo para a prparacao de derivados de diazina e de composicoes farmaceuticas que os contem
ES2209421T3 (es)	2004-06-16	Compuestos de pirimididona, composiciones farmaceuticas que contienen los compuestos, y procedimiento para la preparacion de los mismos.
EP3104861A1 (en)	2016-12-21	Bifunctional compounds and use for reducing uric acid levels
SU1706389A3 (ru)	1992-01-15	Способ получени [5(6)-(1Н-азол-1-ил-метил)-бензимидазол]карбаматов
US20040266791A1 (en)	2004-12-30	Water soluble salts of risperidone
SK4794A3 (en)	1995-01-12	4-pyromidione derivatives salts and pharmaceutical compositions containing this derivatives
WO1998027982A1 (fr)	1998-07-02	Composition contenant de l'acide ascorbique
FI61872B (fi)	1982-06-30	Derivat av trijoderade aminobensenkarboxylsyror anvaenda som roentgenkontrastmedel
AU2005240733A1 (en)	2005-11-17	Novel beta agonists, method for producing the same and their use as drugs
JP2009541410A5 (xx)	2010-07-22
JPS59118786A (ja)	1984-07-09	新規な薬理学的に活性なピラゾロピリジン類
CA2150609C (en)	1998-12-08	Pyrimidine derivatives and pharmaceutical composition
US5912261A (en)	1999-06-15	Carboxyalkyl heterocyclic derivatives
JPH02138263A (ja)	1990-05-28	イミダゾール誘導体およびその製造法ならびにこれを含有する抗潰瘍剤
CA2627090A1 (en)	2007-05-03	Benzimidazole derivatives for use as beta-3 receptor agonists
AU2015340613B2 (en)	2020-03-12	Derivatives of 2-(1,2,4-triazol-3-ylsulfanyl)-N-1,3,4-thiadiazol-2-yl acetamide which are useful for the treatment of inter alia diabetes
RU2259371C2 (ru)	2005-08-27	Замещенные 5r1,6r2 1,3,4-тиадиазин-2 амины и содержащие их фармацевтические композиции в качестве фармакологически активных средств, обладающих антикоагулянтным и антиагрегантным действием
CA2627403A1 (en)	2007-05-03	Imidazo-pyridine containing beta agonists, method for producing them and their use as drugs
CN112194660A (zh)	2021-01-08	一种pde2抑制剂苯基吡唑并嘧啶类化合物及其制备方法
US6303608B1 (en)	2001-10-16	2-{4-[4-(4,5-dichloro-2-methylimidazol-1-yl)butyl]-1-piperazinyl}-5-fluoropyrimidine, its preparation and its therapeutic use
BRPI0903803A2 (pt)	2011-06-07	composto, isÈmero do composto, processo de sua preparação, composto intermediário, composição farmacêutica; medicamento, uso dos compostos e método de tratamento
US3468889A (en)	1969-09-23	O-and/or s-nicotinoyl diacylthiamines and acylation process for preparing the same